| abstract |
Cancer patients who are eligible for Bcl-2 family inhibitor treatment, including assessing the expression levels of the combinations of biomarkers listed in Tables 1, 2, 3, 4, 5 or 6 in patient tissue samples Methods to Identify and Monitor Patient Response to Bcl-2 Family Inhibitor Treatment. The methods of the present invention allow for more effective identification of patients to receive Bcl-2 family inhibitor treatment and to determine patient response to treatment. |